drug_type
RELEVANT_DRUG
intervention_type
Drug
drug_description
A bispecific IgG antibody immunotherapy that binds BCMA on malignant plasma cells and CD3 on T cells, forming an immune synapse to activate T cells and kill BCMA-positive tumor cells via cytotoxic granule release and cytokine-mediated responses.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Elranatamab
drug_category
BISPECIFIC T ENGAGER
drug_class
Engager
drug_delivery_route
Subcutaneous
drug_mechanism_of_action
Elranatamab is a bispecific IgG antibody that binds BCMA on malignant plasma cells and CD3 on T cells, bringing them into proximity to form an immune synapse. This activates T cells to kill BCMA-positive tumor cells via cytotoxic granule release and cytokine-mediated responses.
drug_name
Elranatamab (PF-06863135)
nct_id_drug_ref
NCT06592222